📰 Maxcyte Daily News
Maxcyte Daily News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Maxcyte Daily. Real-time updates on events, politics, business and more.
June 11, 2024
MaxCyte, Inc. (NASDAQ:MXCT – Get Free Report) CEO Maher Masoud acquired 70,443 shares of the stock in a transaction dated Monday, June 10th. The stock was bought at an average cost of $4.90 per share, with a total value of $345,170.70. Following the completion of the purchase, the chief executive officer now owns 100,000 shares […]
June 10, 2024
Cadian Capital Management LP bought a new position in shares of MaxCyte, Inc. (NASDAQ:MXCT – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,644,898 shares of the company’s stock, valued at approximately $26,531,000. MaxCyte comprises 1.1% of Cadian Capital […]
June 10, 2024
Cadian Capital Management LP acquired a new position in MaxCyte, Inc. (NASDAQ:MXCT – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 5,644,898 shares of the company’s stock, valued at approximately $26,531,000. MaxCyte comprises about 1.1% of Cadian […]
April 29, 2024
Valmark Advisers Inc. bought a new stake in MaxCyte, Inc. (NASDAQ:MXCT – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 83,927 shares of the company’s stock, valued at approximately $394,000. Valmark Advisers Inc. owned about 0.08% of MaxCyte […]
April 27, 2024
Stephens reaffirmed their overweight rating on shares of MaxCyte (NASDAQ:MXCT – Free Report) in a report published on Tuesday, Benzinga reports. The firm currently has a $11.00 price target on the stock. Several other equities analysts have also recently weighed in on the company. BTIG Research lowered their price target on MaxCyte from $10.00 to […]
March 9, 2024
William Blair reaffirmed their outperform rating on shares of MaxCyte (NASDAQ:MXCT – Free Report) in a report published on Tuesday morning, RTT News reports. Separately, Craig Hallum started coverage on MaxCyte in a research note on Wednesday, November 29th. They issued a buy rating and a $7.00 target price on the stock. View Our Latest […]
February 2, 2024
MaxCyte, Inc. (NASDAQ:MXCT – Get Free Report) Director John Joseph Johnston sold 5,000 shares of MaxCyte stock in a transaction on Friday, January 26th. The shares were sold at an average price of $5.12, for a total transaction of $25,600.00. Following the completion of the sale, the director now owns 120,583 shares in the company, […]
January 11, 2024
MaxCyte, Inc. (NASDAQ:MXCT – Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $4.59, but opened at $4.98. MaxCyte shares last traded at $5.14, with a volume of 235,852 shares changing hands. Wall Street Analyst Weigh In Several research firms have recently issued reports on MXCT. Stephens […]
December 14, 2023
MaxCyte, Inc. (NASDAQ:MXCT – Free Report) – William Blair lifted their FY2023 EPS estimates for MaxCyte in a research note issued to investors on Tuesday, December 12th. William Blair analyst M. Larew now forecasts that the company will post earnings per share of ($0.41) for the year, up from their prior forecast of ($0.45). William […]
December 3, 2023
MaxCyte, Inc. (LON:MXCT – Get Free Report) insider John Johnston sold 200 shares of the stock in a transaction that occurred on Monday, November 27th. The stock was sold at an average price of GBX 453 ($5.72), for a total transaction of £906 ($1,144.37). MaxCyte Stock Down 0.7 % MXCT opened at GBX 375 ($4.74) […]